Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Sep. 27, 2013	Sep. 28, 2012
Cash flows from operating activities:
Net loss	$ (1,503,000)	$ (2,280,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	463,000	395,000
Amortization of intangible assets	509,000	583,000
Amortization of debt discount	96,000
Stock based compensation expense	70,000	78,000
Change in fair value of warrant liability	89,000	(13,000)
Changes in operating assets and liabilities:
Accounts receivable - net	(674,000)	(329,000)
Inventories	(712,000)	(112,000)
Prepaid expenses and other assets	15,000	(237,000)
Accounts payable and accrued expenses	1,172,000	686,000
Net cash used in operating activities	(475,000)	(1,229,000)
Cash flows from investing activities:
Capital expenditures	(93,000)	(198,000)
Patent expenditures	(127,000)	(69,000)
Net cash used in investing activities	(220,000)	(267,000)
Cash flows from financing activities:
Payments on bank term loan	(167,000)	(167,000)
Net proceeds on bank line of credit	1,251,000	300,000
Payments on MEDC/MSF term loans	(276,000)	(262,000)
Payments on PFG term loan	(357,000)
Payments on capital lease	(3,000)
Taxes paid on net share settlement	(2,000)
Proceeds from exercise of stock options	1,000
Net cash (used in) provided by financing activities	447,000	(129,000)
Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents	(248,000)	(1,625,000)
Cash and cash equivalents at beginning of period	619,000	3,249,000
Cash and cash equivalents at end of period	371,000	1,624,000
Supplemental disclosure of cash flow information:
Cash paid for interest	193,000	58,000
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of equipment through-capital lease	$ 50,000